abstract |
Tumor formation causes dysfunction of the PI3K pathway, a signaling pathway. There is a need for methods of predicting inhibitors that inhibit over-expressed and abnormally activated P13K. There is also a need for a predictive biomarker assay that examines multiple major signaling pathways that can be used to determine the clinical susceptibility of a particular target to inhibitor alone and / or inhibitor-combination therapy. A method is provided for detecting, measuring, and quantifying the state of expression and activation of a signaling analyte that includes the P13K pathway in a cell, such as a tumor cell. Also provided are methods for selecting treatment, optimizing treatment, monitoring treatment efficacy, and / or detecting treatment resistance. Thus, the method is useful for improving cancer treatment choices and disease monitoring. [Selection] FIG. 3A |